Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

Human papillomavirus and HPV vaccines: a review.

Cutts FT, Franceschi S, Goldie S, Castellsague X, de Sanjose S, Garnett G, Edmunds WJ, Claeys P, Goldenthal KL, Harper DM, Markowitz L.

Bull World Health Organ. 2007 Sep;85(9):719-26. Review.

2.

Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).

Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER; Centers for Disease Control and Prevention (CDC).; Advisory Committee on Immunization Practices (ACIP)..

MMWR Recomm Rep. 2007 Mar 23;56(RR-2):1-24.

3.
7.

Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis.

Van de Velde N, Boily MC, Drolet M, Franco EL, Mayrand MH, Kliewer EV, Coutlée F, Laprise JF, Malagón T, Brisson M.

J Natl Cancer Inst. 2012 Nov 21;104(22):1712-23. doi: 10.1093/jnci/djs395. Epub 2012 Oct 27.

PMID:
23104323
8.

HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives.

Castellsagué X, Schneider A, Kaufmann AM, Bosch FX.

Gynecol Oncol. 2009 Dec;115(3 Suppl):S15-23. doi: 10.1016/j.ygyno.2009.09.021. Epub 2009 Oct 12.

PMID:
19819540
10.
12.

Spotlight on AS04-adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix®).

McKeage K, Romanowski B.

BioDrugs. 2011 Aug 1;25(4):265-9. doi: 10.2165/11206830-000000000-00000.

PMID:
21815703
13.

[Human papillomavirus prophylactic vaccines: stakes and perspectives].

Hantz S, Alain S, Denis F.

Gynecol Obstet Fertil. 2006 Jul-Aug;34(7-8):647-55. Epub 2006 Jun 27. Review. French.

PMID:
16807045
14.

Cost-consequences evaluation between bivalent and quadrivalent HPV vaccines in Italy: the potential impact of different cross-protection profiles.

Capri S, Gasparini R, Panatto D, Demarteau N.

Gynecol Oncol. 2011 Jun 1;121(3):514-21. doi: 10.1016/j.ygyno.2011.01.029. Epub 2011 Feb 19.

PMID:
21334734
15.

High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up.

Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen OE, Olsson SE, Høye J, Steinwall M, Riis-Johannessen G, Andersson-Ellstrom A, Elfgren K, Krogh Gv, Lehtinen M, Malm C, Tamms GM, Giacoletti K, Lupinacci L, Railkar R, Taddeo FJ, Bryan J, Esser MT, Sings HL, Saah AJ, Barr E.

Br J Cancer. 2006 Dec 4;95(11):1459-66. Epub 2006 Nov 21.

16.

Quadrivalent human papillomavirus vaccine.

Barr E, Tamms G.

Clin Infect Dis. 2007 Sep 1;45(5):609-7. Epub 2007 Jul 25. Review.

PMID:
17682997
17.

Clinical trials of human papillomavirus vaccines and beyond.

Lehtinen M, Dillner J.

Nat Rev Clin Oncol. 2013 Jul;10(7):400-10. doi: 10.1038/nrclinonc.2013.84. Epub 2013 Jun 4. Review. Erratum in: Nat Rev Clin Oncol. 2015 Jan;12(1). doi:10.1038/nrclinonc.2014.204.

PMID:
23736648
18.

Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial.

Muñoz N, Manalastas R Jr, Pitisuttithum P, Tresukosol D, Monsonego J, Ault K, Clavel C, Luna J, Myers E, Hood S, Bautista O, Bryan J, Taddeo FJ, Esser MT, Vuocolo S, Haupt RM, Barr E, Saah A.

Lancet. 2009 Jun 6;373(9679):1949-57. doi: 10.1016/S0140-6736(09)60691-7. Epub 2009 Jun 1.

PMID:
19493565
19.

Human Pappilomavirus (HPV) induced cancers and prevention by immunization.

Khaliq SA, Shyum Naqvi SB, Fatima A.

Pak J Pharm Sci. 2012 Oct;25(4):763-72.

PMID:
23009992
20.

Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses.

Barnabas RV, Laukkanen P, Koskela P, Kontula O, Lehtinen M, Garnett GP.

PLoS Med. 2006 May;3(5):e138. Epub 2006 Apr 4.

Supplemental Content

Support Center